Arnaud Lesegretain

Outlook Microsoft Office 365 Microsoft Azure Hosting Salesforce Eloqua Freshdesk VueJS React Redux The Trade Desk reCAPTCHA Google Font API Google Tag Manager Mobile Friendly ASP.NET Microsoft-IIS Google Dynamic Remarketing Hotjar DoubleClick Conversion DoubleClick Render AI

nuclear medicine nuclear industry biotechnology pharmaceutical clinical trial biotechnology research targeted alpha therapy lead-212 alpha-emitting radioisotope cancer treatment biological vectors peptide radioligand antibody conjugation radiopharmaceuticals clinical trials oncology research payload delivery high-purity isotopes supply chain reliability drug development pipeline preclinical studies dose optimization safety profile tumor targeting cytotoxic potential metastatic tumors neuroendocrine tumors solid tumors enhanced efficacy manufacturing capacity commercial production theranostics patient-centric design bioconjugation technology proprietary processes regulatory approvals fda designation patient eligibility collaboration with biotech pharmaceutical partnerships advanced imaging techniques in vivo efficacy molecular imaging alpha emitters radioligand therapy customized therapeutics chemistry & process engineering peptide therapy optimization of drug delivery tumor receptor targeting comprehensive product pipeline innovative therapies high unmet medical need clinical-stage biotechnology targeted cancer therapies targeted alpha therapy (tat) radioligand therapies oncology gmp manufacturing cancer patients unmet medical needs biopharmaceutical partnerships research & development precision medicine therapeutic payloads cancer-specific antigens somatostatin-receptor expressing tumors advanced radiopharmaceuticals healthcare stakeholders biotechnology industry nuclear medicine industry thorium-228 precursor production patient advocacy cancer resistance therapeutic innovation medical health care health wellness & fitness hospital & health care